Magazine Article | May 3, 2021

A Q&A With A COVID-Era New CEO

Source: Life Science Leader

By Dan Schell, Chief Editor, Clinical Leader

Becoming the CEO of a pharma company early in the COVID pandemic would be a big challenge for even a seasoned executive in this industry. Just ask David Horn Solomon, Ph.D., who took on the top role at Pharnext in April 2020. But for him, the challenge was two-fold, because the company recently had its Phase 3 trial data rejected by the FDA (for more on this part of the story, read my colleague Ed Miseta’s article on Clinical Leader called, “A Clinical Setback Leads To A Transformation And A New Trial”). We caught up with Solomon in February 2021 to see what he has accomplished so far as he approaches one year on the job.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader